nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—CYP1A1—Progesterone—uterine cancer	0.0672	0.127	CbGbCtD
Gefitinib—ABCG2—Dactinomycin—uterine cancer	0.0577	0.109	CbGbCtD
Gefitinib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0408	0.0774	CbGbCtD
Gefitinib—CYP3A5—Progesterone—uterine cancer	0.0403	0.0764	CbGbCtD
Gefitinib—ABCG2—Carboplatin—uterine cancer	0.0388	0.0735	CbGbCtD
Gefitinib—ABCG2—Etoposide—uterine cancer	0.0326	0.0617	CbGbCtD
Gefitinib—CYP2C19—Progesterone—uterine cancer	0.0325	0.0616	CbGbCtD
Gefitinib—CYP2C9—Progesterone—uterine cancer	0.0271	0.0513	CbGbCtD
Gefitinib—ABCB1—Progesterone—uterine cancer	0.0263	0.0497	CbGbCtD
Gefitinib—CYP2D6—Progesterone—uterine cancer	0.0247	0.0469	CbGbCtD
Gefitinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0237	0.045	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—uterine cancer	0.0222	0.0421	CbGbCtD
Gefitinib—ABCB1—Dactinomycin—uterine cancer	0.0208	0.0394	CbGbCtD
Gefitinib—CYP3A5—Etoposide—uterine cancer	0.0181	0.0342	CbGbCtD
Gefitinib—CYP3A4—Progesterone—uterine cancer	0.0157	0.0298	CbGbCtD
Gefitinib—ABCB1—Etoposide—uterine cancer	0.0118	0.0223	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—uterine cancer	0.00801	0.0152	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—uterine cancer	0.00755	0.0143	CbGbCtD
Gefitinib—CYP3A4—Etoposide—uterine cancer	0.00704	0.0133	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—uterine cancer	0.0048	0.0091	CbGbCtD
Gefitinib—Lapatinib—ERBB2—uterine cancer	0.00419	0.528	CrCbGaD
Gefitinib—ERBB3—exocrine gland—uterine cancer	0.00353	0.027	CbGeAlD
Gefitinib—CHEK2—myometrium—uterine cancer	0.00319	0.0245	CbGeAlD
Gefitinib—Afatinib—ERBB2—uterine cancer	0.00297	0.374	CrCbGaD
Gefitinib—SBK1—endometrium—uterine cancer	0.00258	0.0198	CbGeAlD
Gefitinib—CHEK2—decidua—uterine cancer	0.00237	0.0182	CbGeAlD
Gefitinib—HIPK4—female reproductive system—uterine cancer	0.00211	0.0162	CbGeAlD
Gefitinib—CSNK1E—myometrium—uterine cancer	0.00203	0.0155	CbGeAlD
Gefitinib—IRAK4—myometrium—uterine cancer	0.00199	0.0153	CbGeAlD
Gefitinib—MKNK2—myometrium—uterine cancer	0.00186	0.0142	CbGeAlD
Gefitinib—MKNK1—myometrium—uterine cancer	0.00183	0.0141	CbGeAlD
Gefitinib—CHEK2—female gonad—uterine cancer	0.00169	0.013	CbGeAlD
Gefitinib—CHEK2—vagina—uterine cancer	0.00168	0.0129	CbGeAlD
Gefitinib—EPHA6—female reproductive system—uterine cancer	0.00167	0.0128	CbGeAlD
Gefitinib—EGFR—uterine cervix—uterine cancer	0.00164	0.0126	CbGeAlD
Gefitinib—CSNK1E—uterine cervix—uterine cancer	0.00158	0.0121	CbGeAlD
Gefitinib—IRAK4—uterine cervix—uterine cancer	0.00155	0.0119	CbGeAlD
Gefitinib—ERBB3—epithelium—uterine cancer	0.00153	0.0118	CbGeAlD
Gefitinib—ERBB3—uterine cervix—uterine cancer	0.00152	0.0117	CbGeAlD
Gefitinib—MAP3K19—female reproductive system—uterine cancer	0.00152	0.0116	CbGeAlD
Gefitinib—STK10—myometrium—uterine cancer	0.00151	0.0116	CbGeAlD
Gefitinib—CSNK1E—decidua—uterine cancer	0.0015	0.0115	CbGeAlD
Gefitinib—IRAK4—decidua—uterine cancer	0.00148	0.0113	CbGeAlD
Gefitinib—MKNK2—epithelium—uterine cancer	0.00146	0.0112	CbGeAlD
Gefitinib—MKNK2—uterine cervix—uterine cancer	0.00145	0.0111	CbGeAlD
Gefitinib—IRAK1—uterine cervix—uterine cancer	0.00145	0.0111	CbGeAlD
Gefitinib—EGFR—mammalian vulva—uterine cancer	0.00143	0.011	CbGeAlD
Gefitinib—MKNK1—uterine cervix—uterine cancer	0.00143	0.0109	CbGeAlD
Gefitinib—CSNK1E—endometrium—uterine cancer	0.00143	0.0109	CbGeAlD
Gefitinib—ERBB3—renal system—uterine cancer	0.00142	0.0109	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—uterine cancer	0.00141	0.0108	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—uterine cancer	0.00141	0.0108	CbGeAlD
Gefitinib—IRAK4—endometrium—uterine cancer	0.0014	0.0108	CbGeAlD
Gefitinib—CSNK1E—mammalian vulva—uterine cancer	0.00138	0.0106	CbGeAlD
Gefitinib—MKNK2—decidua—uterine cancer	0.00138	0.0106	CbGeAlD
Gefitinib—IRAK1—decidua—uterine cancer	0.00138	0.0106	CbGeAlD
Gefitinib—EGFR—uterus—uterine cancer	0.00137	0.0105	CbGeAlD
Gefitinib—MKNK1—decidua—uterine cancer	0.00136	0.0104	CbGeAlD
Gefitinib—IRAK4—mammalian vulva—uterine cancer	0.00136	0.0104	CbGeAlD
Gefitinib—MKNK2—renal system—uterine cancer	0.00135	0.0104	CbGeAlD
Gefitinib—MAP2K5—myometrium—uterine cancer	0.00135	0.0103	CbGeAlD
Gefitinib—CSNK1E—uterus—uterine cancer	0.00131	0.0101	CbGeAlD
Gefitinib—MKNK2—endometrium—uterine cancer	0.00131	0.01	CbGeAlD
Gefitinib—MKNK1—endometrium—uterine cancer	0.00129	0.0099	CbGeAlD
Gefitinib—ERBB3—uterus—uterine cancer	0.00127	0.00971	CbGeAlD
Gefitinib—MKNK2—mammalian vulva—uterine cancer	0.00127	0.0097	CbGeAlD
Gefitinib—IRAK1—mammalian vulva—uterine cancer	0.00127	0.0097	CbGeAlD
Gefitinib—SBK1—lymph node—uterine cancer	0.00125	0.00959	CbGeAlD
Gefitinib—MKNK1—mammalian vulva—uterine cancer	0.00125	0.00957	CbGeAlD
Gefitinib—MKNK2—uterus—uterine cancer	0.00121	0.00924	CbGeAlD
Gefitinib—CSNK1E—female reproductive system—uterine cancer	0.00118	0.00905	CbGeAlD
Gefitinib—STK10—uterine cervix—uterine cancer	0.00118	0.00901	CbGeAlD
Gefitinib—ERBB3—female reproductive system—uterine cancer	0.00114	0.00873	CbGeAlD
Gefitinib—STK10—decidua—uterine cancer	0.00112	0.00859	CbGeAlD
Gefitinib—EGFR—female gonad—uterine cancer	0.00112	0.00856	CbGeAlD
Gefitinib—STK10—renal system—uterine cancer	0.0011	0.00843	CbGeAlD
Gefitinib—CHEK2—lymph node—uterine cancer	0.00109	0.00835	CbGeAlD
Gefitinib—MKNK2—female reproductive system—uterine cancer	0.00108	0.0083	CbGeAlD
Gefitinib—IRAK1—female reproductive system—uterine cancer	0.00108	0.0083	CbGeAlD
Gefitinib—CSNK1E—female gonad—uterine cancer	0.00107	0.00823	CbGeAlD
Gefitinib—MKNK1—female reproductive system—uterine cancer	0.00107	0.0082	CbGeAlD
Gefitinib—CSNK1E—vagina—uterine cancer	0.00107	0.00818	CbGeAlD
Gefitinib—IRAK4—female gonad—uterine cancer	0.00106	0.00811	CbGeAlD
Gefitinib—ERBB3—Podofilox—Etoposide—uterine cancer	0.00105	0.181	CbGdCrCtD
Gefitinib—IRAK4—vagina—uterine cancer	0.00105	0.00806	CbGeAlD
Gefitinib—MAP2K5—uterine cervix—uterine cancer	0.00105	0.00805	CbGeAlD
Gefitinib—ERBB3—female gonad—uterine cancer	0.00104	0.00795	CbGeAlD
Gefitinib—STK10—mammalian vulva—uterine cancer	0.00103	0.00788	CbGeAlD
Gefitinib—MAP2K5—decidua—uterine cancer	0.001	0.00767	CbGeAlD
Gefitinib—MKNK2—female gonad—uterine cancer	0.000986	0.00756	CbGeAlD
Gefitinib—IRAK1—female gonad—uterine cancer	0.000986	0.00756	CbGeAlD
Gefitinib—STK10—uterus—uterine cancer	0.00098	0.00751	CbGeAlD
Gefitinib—MKNK2—vagina—uterine cancer	0.00098	0.00751	CbGeAlD
Gefitinib—MKNK1—female gonad—uterine cancer	0.000973	0.00746	CbGeAlD
Gefitinib—MKNK1—vagina—uterine cancer	0.000967	0.00742	CbGeAlD
Gefitinib—MAP2K5—endometrium—uterine cancer	0.00095	0.00728	CbGeAlD
Gefitinib—MAP2K5—mammalian vulva—uterine cancer	0.000919	0.00704	CbGeAlD
Gefitinib—STK10—female reproductive system—uterine cancer	0.000881	0.00675	CbGeAlD
Gefitinib—STK10—female gonad—uterine cancer	0.000802	0.00614	CbGeAlD
Gefitinib—STK10—vagina—uterine cancer	0.000797	0.00611	CbGeAlD
Gefitinib—MAP2K5—female reproductive system—uterine cancer	0.000787	0.00603	CbGeAlD
Gefitinib—Vandetanib—VEGFA—uterine cancer	0.000774	0.0977	CrCbGaD
Gefitinib—ORM1—endometrium—uterine cancer	0.000771	0.00591	CbGeAlD
Gefitinib—EGFR—lymph node—uterine cancer	0.000718	0.00551	CbGeAlD
Gefitinib—MAP2K5—female gonad—uterine cancer	0.000716	0.00549	CbGeAlD
Gefitinib—CSNK1E—Danazol—Progesterone—uterine cancer	0.000714	0.123	CbGdCrCtD
Gefitinib—MAP2K5—vagina—uterine cancer	0.000711	0.00545	CbGeAlD
Gefitinib—CHEK2—Teniposide—Etoposide—uterine cancer	0.000711	0.122	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—uterine cancer	0.000711	0.122	CbGdCrCtD
Gefitinib—CSNK1E—lymph node—uterine cancer	0.000691	0.00529	CbGeAlD
Gefitinib—IRAK4—lymph node—uterine cancer	0.00068	0.00521	CbGeAlD
Gefitinib—ERBB3—lymph node—uterine cancer	0.000667	0.00511	CbGeAlD
Gefitinib—ABCG2—myometrium—uterine cancer	0.000656	0.00503	CbGeAlD
Gefitinib—ORM1—female reproductive system—uterine cancer	0.000639	0.0049	CbGeAlD
Gefitinib—MKNK2—lymph node—uterine cancer	0.000634	0.00486	CbGeAlD
Gefitinib—IRAK1—lymph node—uterine cancer	0.000634	0.00486	CbGeAlD
Gefitinib—MKNK1—lymph node—uterine cancer	0.000626	0.0048	CbGeAlD
Gefitinib—STK10—lymph node—uterine cancer	0.000515	0.00395	CbGeAlD
Gefitinib—ABCG2—uterine cervix—uterine cancer	0.000511	0.00392	CbGeAlD
Gefitinib—CHEK2—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.000504	0.0869	CbGdCrCtD
Gefitinib—CYP1A1—epithelium—uterine cancer	0.000489	0.00375	CbGeAlD
Gefitinib—ABCG2—decidua—uterine cancer	0.000487	0.00373	CbGeAlD
Gefitinib—CYP1A1—uterine cervix—uterine cancer	0.000485	0.00372	CbGeAlD
Gefitinib—CYP3A5—uterine cervix—uterine cancer	0.000474	0.00363	CbGeAlD
Gefitinib—ABCG2—endometrium—uterine cancer	0.000462	0.00354	CbGeAlD
Gefitinib—MAP2K5—lymph node—uterine cancer	0.00046	0.00353	CbGeAlD
Gefitinib—CYP1A1—renal system—uterine cancer	0.000454	0.00348	CbGeAlD
Gefitinib—ABCG2—mammalian vulva—uterine cancer	0.000447	0.00343	CbGeAlD
Gefitinib—CYP3A5—renal system—uterine cancer	0.000444	0.0034	CbGeAlD
Gefitinib—Rash pustular—Doxorubicin—uterine cancer	0.00044	0.00259	CcSEcCtD
Gefitinib—CHEK2—Testosterone Propionate—Progesterone—uterine cancer	0.00044	0.0758	CbGdCrCtD
Gefitinib—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000436	0.00257	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Etoposide—uterine cancer	0.000433	0.00255	CcSEcCtD
Gefitinib—ABCG2—uterus—uterine cancer	0.000426	0.00326	CbGeAlD
Gefitinib—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000425	0.0025	CcSEcCtD
Gefitinib—CYP1A1—mammalian vulva—uterine cancer	0.000424	0.00325	CbGeAlD
Gefitinib—Dyspnoea—Progesterone—uterine cancer	0.000421	0.00248	CcSEcCtD
Gefitinib—Shock—Medroxyprogesterone Acetate—uterine cancer	0.000421	0.00248	CcSEcCtD
Gefitinib—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000419	0.00247	CcSEcCtD
Gefitinib—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000419	0.00246	CcSEcCtD
Gefitinib—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000415	0.00245	CcSEcCtD
Gefitinib—Alopecia—Dactinomycin—uterine cancer	0.000415	0.00244	CcSEcCtD
Gefitinib—Decreased appetite—Progesterone—uterine cancer	0.00041	0.00242	CcSEcCtD
Gefitinib—CYP2C19—vagina—uterine cancer	0.000408	0.00313	CbGeAlD
Gefitinib—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000408	0.0024	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Progesterone—uterine cancer	0.000408	0.0024	CcSEcCtD
Gefitinib—Fatigue—Progesterone—uterine cancer	0.000407	0.0024	CcSEcCtD
Gefitinib—CYP1A1—uterus—uterine cancer	0.000404	0.0031	CbGeAlD
Gefitinib—Constipation—Progesterone—uterine cancer	0.000404	0.00238	CcSEcCtD
Gefitinib—Pain—Progesterone—uterine cancer	0.000404	0.00238	CcSEcCtD
Gefitinib—Ulcer—Epirubicin—uterine cancer	0.000401	0.00236	CcSEcCtD
Gefitinib—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.0004	0.00235	CcSEcCtD
Gefitinib—Gastrointestinal pain—Progesterone—uterine cancer	0.000386	0.00227	CcSEcCtD
Gefitinib—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000381	0.00224	CcSEcCtD
Gefitinib—Pneumonia—Etoposide—uterine cancer	0.000381	0.00224	CcSEcCtD
Gefitinib—Infestation NOS—Etoposide—uterine cancer	0.000379	0.00223	CcSEcCtD
Gefitinib—Infestation—Etoposide—uterine cancer	0.000379	0.00223	CcSEcCtD
Gefitinib—Anaemia—Dactinomycin—uterine cancer	0.000378	0.00222	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000375	0.00221	CcSEcCtD
Gefitinib—Urticaria—Progesterone—uterine cancer	0.000375	0.00221	CcSEcCtD
Gefitinib—ORM1—lymph node—uterine cancer	0.000374	0.00286	CbGeAlD
Gefitinib—Abdominal pain—Progesterone—uterine cancer	0.000373	0.0022	CcSEcCtD
Gefitinib—Body temperature increased—Progesterone—uterine cancer	0.000373	0.0022	CcSEcCtD
Gefitinib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000372	0.00219	CcSEcCtD
Gefitinib—Ulcer—Doxorubicin—uterine cancer	0.000371	0.00218	CcSEcCtD
Gefitinib—Melaena—Epirubicin—uterine cancer	0.000371	0.00218	CcSEcCtD
Gefitinib—Cystitis noninfective—Epirubicin—uterine cancer	0.000371	0.00218	CcSEcCtD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—uterine cancer	0.000371	0.0639	CbGdCrCtD
Gefitinib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000369	0.00217	CcSEcCtD
Gefitinib—Stomatitis—Etoposide—uterine cancer	0.000369	0.00217	CcSEcCtD
Gefitinib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000369	0.00217	CcSEcCtD
Gefitinib—Malaise—Dactinomycin—uterine cancer	0.000369	0.00217	CcSEcCtD
Gefitinib—Cystitis—Epirubicin—uterine cancer	0.000366	0.00216	CcSEcCtD
Gefitinib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000366	0.00215	CcSEcCtD
Gefitinib—CHEK2—Danazol—Progesterone—uterine cancer	0.000366	0.063	CbGdCrCtD
Gefitinib—CYP1A1—female reproductive system—uterine cancer	0.000363	0.00278	CbGeAlD
Gefitinib—Hepatobiliary disease—Etoposide—uterine cancer	0.000358	0.00211	CcSEcCtD
Gefitinib—Dry eye—Epirubicin—uterine cancer	0.00035	0.00206	CcSEcCtD
Gefitinib—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00035	0.00206	CcSEcCtD
Gefitinib—CYP2C9—female reproductive system—uterine cancer	0.00035	0.00268	CbGeAlD
Gefitinib—ABCG2—female gonad—uterine cancer	0.000348	0.00267	CbGeAlD
Gefitinib—Hypersensitivity—Progesterone—uterine cancer	0.000348	0.00205	CcSEcCtD
Gefitinib—ABCG2—vagina—uterine cancer	0.000346	0.00265	CbGeAlD
Gefitinib—Mouth ulceration—Epirubicin—uterine cancer	0.000343	0.00202	CcSEcCtD
Gefitinib—Bladder pain—Epirubicin—uterine cancer	0.000343	0.00202	CcSEcCtD
Gefitinib—Melaena—Doxorubicin—uterine cancer	0.000343	0.00202	CcSEcCtD
Gefitinib—Cystitis noninfective—Doxorubicin—uterine cancer	0.000343	0.00202	CcSEcCtD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—uterine cancer	0.000343	0.0591	CbGdCrCtD
Gefitinib—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00034	0.002	CcSEcCtD
Gefitinib—Cystitis—Doxorubicin—uterine cancer	0.000339	0.00199	CcSEcCtD
Gefitinib—Asthenia—Progesterone—uterine cancer	0.000339	0.00199	CcSEcCtD
Gefitinib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000338	0.00199	CcSEcCtD
Gefitinib—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000338	0.00199	CcSEcCtD
Gefitinib—Urinary tract disorder—Etoposide—uterine cancer	0.000336	0.00198	CcSEcCtD
Gefitinib—Pruritus—Progesterone—uterine cancer	0.000334	0.00197	CcSEcCtD
Gefitinib—Urethral disorder—Etoposide—uterine cancer	0.000333	0.00196	CcSEcCtD
Gefitinib—CYP3A4—renal system—uterine cancer	0.000333	0.00255	CbGeAlD
Gefitinib—Infection—Dactinomycin—uterine cancer	0.000331	0.00195	CcSEcCtD
Gefitinib—CYP1A1—female gonad—uterine cancer	0.000331	0.00253	CbGeAlD
Gefitinib—CHEK2—Norethindrone—Progesterone—uterine cancer	0.000329	0.0568	CbGdCrCtD
Gefitinib—CYP1A1—vagina—uterine cancer	0.000329	0.00252	CbGeAlD
Gefitinib—ALB—lymph node—uterine cancer	0.000328	0.00251	CbGeAlD
Gefitinib—CYP2D6—renal system—uterine cancer	0.000328	0.00251	CbGeAlD
Gefitinib—Thrombocytopenia—Dactinomycin—uterine cancer	0.000327	0.00192	CcSEcCtD
Gefitinib—Dry eye—Doxorubicin—uterine cancer	0.000324	0.00191	CcSEcCtD
Gefitinib—ABCB1—myometrium—uterine cancer	0.000324	0.00248	CbGeAlD
Gefitinib—CYP3A5—female gonad—uterine cancer	0.000323	0.00248	CbGeAlD
Gefitinib—Diarrhoea—Progesterone—uterine cancer	0.000323	0.0019	CcSEcCtD
Gefitinib—Erythema multiforme—Etoposide—uterine cancer	0.000321	0.00189	CcSEcCtD
Gefitinib—CYP3A5—vagina—uterine cancer	0.000321	0.00246	CbGeAlD
Gefitinib—Thrombophlebitis—Epirubicin—uterine cancer	0.000318	0.00187	CcSEcCtD
Gefitinib—Anorexia—Dactinomycin—uterine cancer	0.000318	0.00187	CcSEcCtD
Gefitinib—Eye disorder—Etoposide—uterine cancer	0.000318	0.00187	CcSEcCtD
Gefitinib—Bladder pain—Doxorubicin—uterine cancer	0.000317	0.00187	CcSEcCtD
Gefitinib—Mouth ulceration—Doxorubicin—uterine cancer	0.000317	0.00187	CcSEcCtD
Gefitinib—Cardiac disorder—Etoposide—uterine cancer	0.000315	0.00186	CcSEcCtD
Gefitinib—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000315	0.00185	CcSEcCtD
Gefitinib—Angiopathy—Etoposide—uterine cancer	0.000308	0.00181	CcSEcCtD
Gefitinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000307	0.00181	CcSEcCtD
Gefitinib—Hepatic failure—Epirubicin—uterine cancer	0.000306	0.0018	CcSEcCtD
Gefitinib—Mediastinal disorder—Etoposide—uterine cancer	0.000306	0.0018	CcSEcCtD
Gefitinib—Eye pain—Epirubicin—uterine cancer	0.000305	0.0018	CcSEcCtD
Gefitinib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000303	0.00178	CcSEcCtD
Gefitinib—Alopecia—Etoposide—uterine cancer	0.0003	0.00177	CcSEcCtD
Gefitinib—Vomiting—Progesterone—uterine cancer	0.0003	0.00177	CcSEcCtD
Gefitinib—Rash—Progesterone—uterine cancer	0.000298	0.00175	CcSEcCtD
Gefitinib—Dermatitis—Progesterone—uterine cancer	0.000297	0.00175	CcSEcCtD
Gefitinib—Thrombophlebitis—Doxorubicin—uterine cancer	0.000294	0.00173	CcSEcCtD
Gefitinib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000293	0.00172	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000292	0.00172	CcSEcCtD
Gefitinib—Decreased appetite—Dactinomycin—uterine cancer	0.00029	0.00171	CcSEcCtD
Gefitinib—Dermatitis bullous—Epirubicin—uterine cancer	0.000288	0.0017	CcSEcCtD
Gefitinib—Fatigue—Dactinomycin—uterine cancer	0.000288	0.00169	CcSEcCtD
Gefitinib—Pain—Dactinomycin—uterine cancer	0.000285	0.00168	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—uterine cancer	0.000284	0.00167	CcSEcCtD
Gefitinib—Eye pain—Doxorubicin—uterine cancer	0.000282	0.00166	CcSEcCtD
Gefitinib—Nausea—Progesterone—uterine cancer	0.00028	0.00165	CcSEcCtD
Gefitinib—Anaemia—Etoposide—uterine cancer	0.000273	0.00161	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000273	0.00161	CcSEcCtD
Gefitinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.0016	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.00027	0.00159	CcSEcCtD
Gefitinib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00027	0.00159	CcSEcCtD
Gefitinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000269	0.00159	CcSEcCtD
Gefitinib—Malaise—Etoposide—uterine cancer	0.000267	0.00157	CcSEcCtD
Gefitinib—Dermatitis bullous—Doxorubicin—uterine cancer	0.000267	0.00157	CcSEcCtD
Gefitinib—CYP3A4—female reproductive system—uterine cancer	0.000267	0.00204	CbGeAlD
Gefitinib—Abdominal pain—Dactinomycin—uterine cancer	0.000264	0.00155	CcSEcCtD
Gefitinib—Body temperature increased—Dactinomycin—uterine cancer	0.000264	0.00155	CcSEcCtD
Gefitinib—CYP2D6—female reproductive system—uterine cancer	0.000262	0.00201	CbGeAlD
Gefitinib—CHEK2—Levonorgestrel—Progesterone—uterine cancer	0.000262	0.0452	CbGdCrCtD
Gefitinib—Cough—Etoposide—uterine cancer	0.000258	0.00152	CcSEcCtD
Gefitinib—Dehydration—Epirubicin—uterine cancer	0.000256	0.00151	CcSEcCtD
Gefitinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000254	0.0015	CcSEcCtD
Gefitinib—ABCB1—epithelium—uterine cancer	0.000254	0.00195	CbGeAlD
Gefitinib—Dry skin—Epirubicin—uterine cancer	0.000252	0.00149	CcSEcCtD
Gefitinib—ABCB1—uterine cervix—uterine cancer	0.000252	0.00193	CbGeAlD
Gefitinib—Hypokalaemia—Epirubicin—uterine cancer	0.000251	0.00148	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.00025	0.00147	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000248	0.00146	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000248	0.00146	CcSEcCtD
Gefitinib—Hypersensitivity—Dactinomycin—uterine cancer	0.000246	0.00145	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000243	0.00143	CcSEcCtD
Gefitinib—ABCB1—decidua—uterine cancer	0.00024	0.00184	CbGeAlD
Gefitinib—Infection—Etoposide—uterine cancer	0.00024	0.00141	CcSEcCtD
Gefitinib—Asthenia—Dactinomycin—uterine cancer	0.000239	0.00141	CcSEcCtD
Gefitinib—CYP2D6—female gonad—uterine cancer	0.000239	0.00183	CbGeAlD
Gefitinib—Dehydration—Doxorubicin—uterine cancer	0.000237	0.00139	CcSEcCtD
Gefitinib—Thrombocytopenia—Etoposide—uterine cancer	0.000236	0.00139	CcSEcCtD
Gefitinib—ABCB1—renal system—uterine cancer	0.000236	0.00181	CbGeAlD
Gefitinib—Skin disorder—Etoposide—uterine cancer	0.000235	0.00138	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—uterine cancer	0.000234	0.00137	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—uterine cancer	0.000233	0.00137	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—uterine cancer	0.000232	0.00136	CcSEcCtD
Gefitinib—Anorexia—Etoposide—uterine cancer	0.00023	0.00135	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000229	0.00135	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000229	0.00135	CcSEcCtD
Gefitinib—Diarrhoea—Dactinomycin—uterine cancer	0.000228	0.00134	CcSEcCtD
Gefitinib—ABCB1—endometrium—uterine cancer	0.000228	0.00175	CbGeAlD
Gefitinib—Hypotension—Etoposide—uterine cancer	0.000226	0.00133	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000225	0.00132	CcSEcCtD
Gefitinib—ABCG2—lymph node—uterine cancer	0.000224	0.00172	CbGeAlD
Gefitinib—ABCB1—mammalian vulva—uterine cancer	0.00022	0.00169	CbGeAlD
Gefitinib—Pancreatitis—Doxorubicin—uterine cancer	0.000216	0.00127	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—uterine cancer	0.000215	0.00127	CcSEcCtD
Gefitinib—Dyspnoea—Etoposide—uterine cancer	0.000215	0.00127	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—uterine cancer	0.000213	0.00126	CcSEcCtD
Gefitinib—CYP1A1—lymph node—uterine cancer	0.000213	0.00163	CbGeAlD
Gefitinib—Infestation NOS—Epirubicin—uterine cancer	0.000212	0.00125	CcSEcCtD
Gefitinib—Infestation—Epirubicin—uterine cancer	0.000212	0.00125	CcSEcCtD
Gefitinib—Vomiting—Dactinomycin—uterine cancer	0.000212	0.00125	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.00021	0.00124	CcSEcCtD
Gefitinib—Rash—Dactinomycin—uterine cancer	0.00021	0.00124	CcSEcCtD
Gefitinib—ABCB1—uterus—uterine cancer	0.00021	0.00161	CbGeAlD
Gefitinib—Decreased appetite—Etoposide—uterine cancer	0.00021	0.00124	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000208	0.00123	CcSEcCtD
Gefitinib—Fatigue—Etoposide—uterine cancer	0.000208	0.00123	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—uterine cancer	0.000207	0.00122	CcSEcCtD
Gefitinib—Pain—Etoposide—uterine cancer	0.000206	0.00122	CcSEcCtD
Gefitinib—Constipation—Etoposide—uterine cancer	0.000206	0.00122	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—uterine cancer	0.000206	0.00121	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—uterine cancer	0.000202	0.00119	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000201	0.00118	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—uterine cancer	0.0002	0.00118	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—uterine cancer	0.000199	0.00117	CcSEcCtD
Gefitinib—Nausea—Dactinomycin—uterine cancer	0.000198	0.00117	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—uterine cancer	0.000198	0.00116	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—uterine cancer	0.000197	0.00116	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—uterine cancer	0.000196	0.00116	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—uterine cancer	0.000196	0.00116	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000195	0.00115	CcSEcCtD
Gefitinib—Urticaria—Etoposide—uterine cancer	0.000192	0.00113	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—uterine cancer	0.000191	0.00113	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—uterine cancer	0.000191	0.00113	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—uterine cancer	0.000191	0.00112	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—uterine cancer	0.000191	0.00112	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—uterine cancer	0.000191	0.00112	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—uterine cancer	0.000191	0.00112	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—uterine cancer	0.000191	0.00112	CcSEcCtD
Gefitinib—ABCB1—female reproductive system—uterine cancer	0.000189	0.00145	CbGeAlD
Gefitinib—Urinary tract disorder—Epirubicin—uterine cancer	0.000188	0.00111	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—uterine cancer	0.000188	0.0011	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—uterine cancer	0.000187	0.0011	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—uterine cancer	0.000187	0.0011	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000186	0.00109	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—uterine cancer	0.000185	0.00109	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—uterine cancer	0.00018	0.00106	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—uterine cancer	0.000178	0.00105	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—uterine cancer	0.000178	0.00105	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—uterine cancer	0.000177	0.00104	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—uterine cancer	0.000177	0.00104	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—uterine cancer	0.000176	0.00104	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—uterine cancer	0.000176	0.00104	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000174	0.00102	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—uterine cancer	0.000174	0.00102	CcSEcCtD
Gefitinib—Asthenia—Etoposide—uterine cancer	0.000173	0.00102	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—uterine cancer	0.000173	0.00102	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—uterine cancer	0.000173	0.00102	CcSEcCtD
Gefitinib—ABCB1—female gonad—uterine cancer	0.000172	0.00132	CbGeAlD
Gefitinib—Mediastinal disorder—Epirubicin—uterine cancer	0.000172	0.00101	CcSEcCtD
Gefitinib—Pruritus—Etoposide—uterine cancer	0.000171	0.00101	CcSEcCtD
Gefitinib—ABCB1—vagina—uterine cancer	0.000171	0.00131	CbGeAlD
Gefitinib—Arrhythmia—Epirubicin—uterine cancer	0.00017	0.001	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—uterine cancer	0.000168	0.000991	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—uterine cancer	0.000167	0.000981	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—uterine cancer	0.000166	0.000976	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—uterine cancer	0.000165	0.000972	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—uterine cancer	0.000165	0.00097	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—uterine cancer	0.000164	0.000963	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—uterine cancer	0.00016	0.000941	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—uterine cancer	0.000159	0.000935	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—uterine cancer	0.000157	0.000927	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—uterine cancer	0.000156	0.000917	CcSEcCtD
Gefitinib—Vomiting—Etoposide—uterine cancer	0.000154	0.000904	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—uterine cancer	0.000153	0.000903	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—uterine cancer	0.000153	0.000902	CcSEcCtD
Gefitinib—Rash—Etoposide—uterine cancer	0.000152	0.000896	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—uterine cancer	0.000152	0.000895	CcSEcCtD
Gefitinib—Malaise—Epirubicin—uterine cancer	0.00015	0.00088	CcSEcCtD
Gefitinib—Cough—Epirubicin—uterine cancer	0.000145	0.000852	CcSEcCtD
Gefitinib—Nausea—Etoposide—uterine cancer	0.000143	0.000844	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—uterine cancer	0.000142	0.000835	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00014	0.000825	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—uterine cancer	0.000138	0.000814	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—uterine cancer	0.000138	0.000813	CcSEcCtD
Gefitinib—Infection—Epirubicin—uterine cancer	0.000134	0.000791	CcSEcCtD
Gefitinib—Cough—Doxorubicin—uterine cancer	0.000134	0.000788	CcSEcCtD
Gefitinib—Shock—Epirubicin—uterine cancer	0.000133	0.000784	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—uterine cancer	0.000133	0.000781	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—uterine cancer	0.000133	0.00078	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—uterine cancer	0.000131	0.000774	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.00013	0.000764	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—uterine cancer	0.000129	0.000759	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—uterine cancer	0.000128	0.000752	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—uterine cancer	0.000126	0.000744	CcSEcCtD
Gefitinib—Infection—Doxorubicin—uterine cancer	0.000124	0.000732	CcSEcCtD
Gefitinib—Shock—Doxorubicin—uterine cancer	0.000123	0.000725	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—uterine cancer	0.000123	0.000723	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—uterine cancer	0.000123	0.000722	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—uterine cancer	0.000122	0.000716	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—uterine cancer	0.000121	0.00071	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—uterine cancer	0.000119	0.000703	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—uterine cancer	0.000118	0.000693	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—uterine cancer	0.000117	0.000689	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000117	0.000688	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—uterine cancer	0.000117	0.000687	CcSEcCtD
Gefitinib—Pain—Epirubicin—uterine cancer	0.000116	0.000681	CcSEcCtD
Gefitinib—Constipation—Epirubicin—uterine cancer	0.000116	0.000681	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—uterine cancer	0.000112	0.000657	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—uterine cancer	0.000111	0.000651	CcSEcCtD
Gefitinib—ABCB1—lymph node—uterine cancer	0.00011	0.000846	CbGeAlD
Gefitinib—Decreased appetite—Doxorubicin—uterine cancer	0.000109	0.000641	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000108	0.000636	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—uterine cancer	0.000108	0.000635	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—uterine cancer	0.000108	0.000633	CcSEcCtD
Gefitinib—Pain—Doxorubicin—uterine cancer	0.000107	0.00063	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—uterine cancer	0.000107	0.00063	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—uterine cancer	0.000107	0.00063	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—uterine cancer	0.000107	0.00063	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000102	0.000603	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—uterine cancer	9.97e-05	0.000587	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—uterine cancer	9.95e-05	0.000586	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—uterine cancer	9.9e-05	0.000583	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—uterine cancer	9.9e-05	0.000583	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—uterine cancer	9.71e-05	0.000572	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—uterine cancer	9.58e-05	0.000564	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—uterine cancer	9.26e-05	0.000545	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—uterine cancer	9.23e-05	0.000543	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—uterine cancer	8.99e-05	0.000529	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—uterine cancer	8.86e-05	0.000521	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—uterine cancer	8.61e-05	0.000507	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—uterine cancer	8.57e-05	0.000504	CcSEcCtD
Gefitinib—Rash—Epirubicin—uterine cancer	8.53e-05	0.000502	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—uterine cancer	8.53e-05	0.000502	CcSEcCtD
Gefitinib—Nausea—Epirubicin—uterine cancer	8.04e-05	0.000473	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—uterine cancer	7.96e-05	0.000469	CcSEcCtD
Gefitinib—Rash—Doxorubicin—uterine cancer	7.9e-05	0.000465	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—uterine cancer	7.89e-05	0.000464	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—uterine cancer	7.44e-05	0.000438	CcSEcCtD
Gefitinib—EGFR—Innate Immune System—NRAS—uterine cancer	1.29e-05	8.18e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PTEN—uterine cancer	1.29e-05	8.14e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KRAS—uterine cancer	1.27e-05	8.04e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	1.27e-05	8.03e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKR1C3—uterine cancer	1.27e-05	8.01e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PTEN—uterine cancer	1.26e-05	7.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—KRAS—uterine cancer	1.26e-05	7.97e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.25e-05	7.91e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—AKT1—uterine cancer	1.25e-05	7.9e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NRAS—uterine cancer	1.25e-05	7.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NRAS—uterine cancer	1.24e-05	7.86e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—uterine cancer	1.24e-05	7.85e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.24e-05	7.84e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.23e-05	7.77e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EP300—uterine cancer	1.23e-05	7.76e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP11A1—uterine cancer	1.22e-05	7.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SOCS3—uterine cancer	1.22e-05	7.74e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.21e-05	7.65e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EP300—uterine cancer	1.2e-05	7.62e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—RRM2—uterine cancer	1.2e-05	7.59e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—uterine cancer	1.2e-05	7.59e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ERBB2—uterine cancer	1.19e-05	7.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDH1—uterine cancer	1.17e-05	7.42e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—RRM2—uterine cancer	1.17e-05	7.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN2B—uterine cancer	1.17e-05	7.41e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PIK3CA—uterine cancer	1.17e-05	7.39e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—DCN—uterine cancer	1.16e-05	7.37e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KRAS—uterine cancer	1.16e-05	7.37e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—uterine cancer	1.16e-05	7.35e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKR1C3—uterine cancer	1.15e-05	7.31e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ERBB2—uterine cancer	1.15e-05	7.27e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL2—uterine cancer	1.15e-05	7.26e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NRAS—uterine cancer	1.15e-05	7.26e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—DCN—uterine cancer	1.14e-05	7.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1R—uterine cancer	1.14e-05	7.19e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CXCL8—uterine cancer	1.13e-05	7.16e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—uterine cancer	1.13e-05	7.14e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NRAS—uterine cancer	1.13e-05	7.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KRAS—uterine cancer	1.11e-05	7.04e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CDKN1B—uterine cancer	1.1e-05	6.99e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RRM2—uterine cancer	1.1e-05	6.98e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STAR—uterine cancer	1.1e-05	6.98e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.1e-05	6.98e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP11A1—uterine cancer	1.1e-05	6.94e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AKT1—uterine cancer	1.1e-05	6.94e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MTHFR—uterine cancer	1.1e-05	6.93e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RRM2—uterine cancer	1.09e-05	6.92e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCL8—uterine cancer	1.09e-05	6.9e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—uterine cancer	1.08e-05	6.83e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KRAS—uterine cancer	1.07e-05	6.8e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—DCN—uterine cancer	1.07e-05	6.78e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP11A1—uterine cancer	1.07e-05	6.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—uterine cancer	1.07e-05	6.78e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—PIK3CA—uterine cancer	1.07e-05	6.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KRAS—uterine cancer	1.07e-05	6.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SMAD3—uterine cancer	1.07e-05	6.76e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CDKN1B—uterine cancer	1.06e-05	6.74e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—DCN—uterine cancer	1.06e-05	6.72e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKT1—uterine cancer	1.06e-05	6.7e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—STK11—uterine cancer	1.04e-05	6.61e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP19A1—uterine cancer	1.04e-05	6.61e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CTNNB1—uterine cancer	1.04e-05	6.6e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	1.04e-05	6.56e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKR1C3—uterine cancer	1.04e-05	6.56e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCL8—uterine cancer	1.03e-05	6.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—PIK3CA—uterine cancer	1.02e-05	6.47e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.02e-05	6.46e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGFR2—uterine cancer	1.02e-05	6.45e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTEN—uterine cancer	1.02e-05	6.44e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKR1C3—uterine cancer	1.01e-05	6.4e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.01e-05	6.39e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CTNNB1—uterine cancer	1.01e-05	6.36e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP11A1—uterine cancer	1e-05	6.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERBB2—uterine cancer	9.9e-06	6.26e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—uterine cancer	9.9e-06	6.26e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KRAS—uterine cancer	9.88e-06	6.25e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PIK3CA—uterine cancer	9.88e-06	6.25e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—STK11—uterine cancer	9.87e-06	6.24e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP19A1—uterine cancer	9.87e-06	6.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—PIK3CA—uterine cancer	9.82e-06	6.21e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTEN—uterine cancer	9.8e-06	6.2e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EP300—uterine cancer	9.7e-06	6.14e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—uterine cancer	9.69e-06	6.13e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ERBB2—uterine cancer	9.57e-06	6.06e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—uterine cancer	9.53e-06	6.03e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKR1C3—uterine cancer	9.53e-06	6.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—uterine cancer	9.46e-06	5.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—uterine cancer	9.46e-06	5.98e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKR1C3—uterine cancer	9.45e-06	5.98e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EP300—uterine cancer	9.35e-06	5.92e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.26e-06	5.86e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—uterine cancer	9.19e-06	5.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1B—uterine cancer	9.17e-06	5.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB2—uterine cancer	9.14e-06	5.78e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—uterine cancer	9.14e-06	5.78e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—uterine cancer	9.08e-06	5.75e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL8—uterine cancer	9.08e-06	5.74e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PIK3CA—uterine cancer	9.08e-06	5.74e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—uterine cancer	9.07e-06	5.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP19A1—uterine cancer	8.99e-06	5.69e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—STK11—uterine cancer	8.99e-06	5.69e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—PIK3CA—uterine cancer	8.91e-06	5.64e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1B—uterine cancer	8.86e-06	5.61e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—uterine cancer	8.85e-06	5.6e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—EP300—uterine cancer	8.84e-06	5.6e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.83e-06	5.59e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—uterine cancer	8.78e-06	5.56e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—uterine cancer	8.75e-06	5.53e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—uterine cancer	8.74e-06	5.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ESR1—uterine cancer	8.72e-06	5.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTNNB1—uterine cancer	8.66e-06	5.48e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—POLD1—uterine cancer	8.65e-06	5.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1B—uterine cancer	8.46e-06	5.36e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.44e-06	5.34e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—uterine cancer	8.44e-06	5.34e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—uterine cancer	8.4e-06	5.31e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—uterine cancer	8.38e-06	5.3e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CTNNB1—uterine cancer	8.37e-06	5.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—uterine cancer	8.35e-06	5.29e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—uterine cancer	8.27e-06	5.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—uterine cancer	8.24e-06	5.22e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—uterine cancer	8.24e-06	5.21e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—uterine cancer	8.16e-06	5.16e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	8.1e-06	5.12e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—STK11—uterine cancer	8.07e-06	5.11e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP19A1—uterine cancer	8.07e-06	5.11e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—uterine cancer	8.07e-06	5.11e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.05e-06	5.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—EP300—uterine cancer	8.05e-06	5.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—uterine cancer	8.02e-06	5.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CTNNB1—uterine cancer	8e-06	5.06e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—STK11—uterine cancer	7.88e-06	4.99e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP19A1—uterine cancer	7.88e-06	4.99e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—uterine cancer	7.85e-06	4.97e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—uterine cancer	7.81e-06	4.94e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—uterine cancer	7.79e-06	4.93e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EP300—uterine cancer	7.78e-06	4.93e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—uterine cancer	7.68e-06	4.86e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.58e-06	4.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—uterine cancer	7.53e-06	4.77e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—uterine cancer	7.53e-06	4.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—uterine cancer	7.43e-06	4.7e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—STK11—uterine cancer	7.43e-06	4.7e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP19A1—uterine cancer	7.43e-06	4.7e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—uterine cancer	7.41e-06	4.69e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—uterine cancer	7.41e-06	4.69e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—uterine cancer	7.37e-06	4.66e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP19A1—uterine cancer	7.36e-06	4.66e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—STK11—uterine cancer	7.36e-06	4.66e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—uterine cancer	7.28e-06	4.61e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—uterine cancer	7.28e-06	4.6e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.23e-06	4.57e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RRM2—uterine cancer	7.22e-06	4.57e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	7.17e-06	4.54e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—uterine cancer	7.12e-06	4.51e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—uterine cancer	7.09e-06	4.49e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—DCN—uterine cancer	7e-06	4.43e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—uterine cancer	6.95e-06	4.4e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—uterine cancer	6.94e-06	4.39e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PIK3CA—uterine cancer	6.92e-06	4.38e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.91e-06	4.37e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—uterine cancer	6.76e-06	4.28e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—uterine cancer	6.69e-06	4.23e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	6.64e-06	4.2e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	6.6e-06	4.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.59e-06	4.17e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PIK3CA—uterine cancer	6.54e-06	4.14e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.53e-06	4.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PIK3CA—uterine cancer	6.52e-06	4.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—uterine cancer	6.48e-06	4.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—uterine cancer	6.4e-06	4.05e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—uterine cancer	6.4e-06	4.05e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—uterine cancer	6.33e-06	4e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—uterine cancer	6.27e-06	3.97e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	6.23e-06	3.94e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—uterine cancer	6.09e-06	3.86e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—uterine cancer	6.07e-06	3.84e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—uterine cancer	6.07e-06	3.84e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—uterine cancer	6.05e-06	3.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—uterine cancer	6.03e-06	3.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—uterine cancer	5.98e-06	3.79e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.96e-06	3.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PIK3CA—uterine cancer	5.96e-06	3.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1B—uterine cancer	5.93e-06	3.75e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—uterine cancer	5.92e-06	3.75e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	5.86e-06	3.71e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—uterine cancer	5.81e-06	3.68e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PIK3CA—uterine cancer	5.76e-06	3.64e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—uterine cancer	5.65e-06	3.58e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—uterine cancer	5.6e-06	3.54e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—uterine cancer	5.58e-06	3.53e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—uterine cancer	5.57e-06	3.52e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—uterine cancer	5.53e-06	3.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—uterine cancer	5.51e-06	3.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PIK3CA—uterine cancer	5.5e-06	3.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—uterine cancer	5.46e-06	3.45e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.35e-06	3.38e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—uterine cancer	5.34e-06	3.38e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—uterine cancer	5.33e-06	3.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—uterine cancer	5.32e-06	3.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—uterine cancer	5.2e-06	3.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—uterine cancer	5.09e-06	3.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—uterine cancer	4.93e-06	3.12e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.88e-06	3.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—uterine cancer	4.87e-06	3.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—uterine cancer	4.86e-06	3.08e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STK11—uterine cancer	4.86e-06	3.07e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	4.86e-06	3.07e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—uterine cancer	4.7e-06	2.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—uterine cancer	4.49e-06	2.84e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—uterine cancer	4.37e-06	2.76e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3CA—uterine cancer	4.3e-06	2.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—uterine cancer	4.19e-06	2.65e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—uterine cancer	4.16e-06	2.63e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—uterine cancer	4.12e-06	2.61e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—uterine cancer	3.93e-06	2.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3CA—uterine cancer	3.85e-06	2.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—uterine cancer	3.76e-06	2.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—uterine cancer	3.72e-06	2.36e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—uterine cancer	3.65e-06	2.31e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—uterine cancer	3.59e-06	2.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—uterine cancer	3.56e-06	2.25e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—uterine cancer	3.51e-06	2.22e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—uterine cancer	3.38e-06	2.14e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—uterine cancer	3.29e-06	2.08e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—uterine cancer	3.22e-06	2.04e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—uterine cancer	3.15e-06	1.99e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—uterine cancer	3.14e-06	1.99e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—uterine cancer	3.1e-06	1.96e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3CA—uterine cancer	3.08e-06	1.95e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—uterine cancer	3.08e-06	1.95e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—uterine cancer	2.96e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—uterine cancer	2.94e-06	1.86e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3CA—uterine cancer	2.91e-06	1.84e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3CA—uterine cancer	2.65e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—uterine cancer	2.52e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3CA—uterine cancer	2.38e-06	1.51e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—uterine cancer	2.38e-06	1.5e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3CA—uterine cancer	2.32e-06	1.47e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.19e-06	1.39e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3CA—uterine cancer	2.17e-06	1.37e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—uterine cancer	2.17e-06	1.37e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—uterine cancer	2.03e-06	1.28e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—uterine cancer	1.95e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—uterine cancer	1.94e-06	1.22e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—uterine cancer	1.9e-06	1.2e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—uterine cancer	1.79e-06	1.13e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—uterine cancer	1.77e-06	1.12e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.43e-06	9.06e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—uterine cancer	1.17e-06	7.4e-06	CbGpPWpGaD
